Therapeutic drug monitoring of busulfan in transplantation

Current Pharmaceutical Design

Volumn 14, Issue 20, 2008, Pages 1936-1949

  Russell, James A ^a   Kangarloo, S B ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Busulfan; Hematopoietic stem cell (HSCs); Intravenous (IV) Bu; Malignancies; Therapeutic drug monitoring (TDM)

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETOPOSIDE; FLUDARABINE; LYMPHOCYTE ANTIBODY; MELPHALAN; METRONIDAZOLE; PHENYTOIN; PYRROLE DERIVATIVE; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; AREA UNDER THE CURVE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONVULSION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG TOLERABILITY; FIRST PASS EFFECT; GASTROINTESTINAL TOXICITY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY OF MEDICINE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REVIEW; STOMATITIS; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 52949100982     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208785061382     Document Type: Review

References (162)

1. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic: Stem cell transplantation. Ther Drug Monit 1998; 20: 543-9.
2. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: Does it improve clinical outcome? Clin Pharmacokinet 2000; 39: 155-65.
3. Grochow LB. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20: 18-25.
4. Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: Rationale and pitfalls (review). Anticancer Res 1994; 14: 2363-70.
5. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 1996; 37: 401-8.
6. Andersson BS, GaJewski J, Donato M, Giralt S, Gian V, Wingard J, et al. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 2000; 25(Suppl 2): S35-8.
7. Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study. Biol Blood Marrow Transplant 2000; 6: 548-54.
8. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant 2002; 8: 145-54.
9. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477-85.
10. Cremers S, Schoemaker R, Bredius R, den Hartigh J, Ball L, Twiss I, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002; 53: 386-9.
11. Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Tranplant 2002; 8: 486-92.
12. Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood, Marrow Transplant 2002; 8: 493-500.
13. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-76.
14. Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002; 8: 619-24.
15. Andesson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, et al. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit Biol Blood Marrow Transplant 2003; 9: 722-4.
16. Shimoni A, Bielorai B, Toren A, Hardan I, Avigdor A, Yeshurun M, et al. Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: Myeloablation with reduced toxicity. Exp Hematol 2003; 31: 428-34.
17. Slattery JT. Re: Intravenous versus oral busulfan - perhaps not as different as suggested. Biol Blood Marrow Transplant 2003; 9: 282-4
18. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-64.
19. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: A novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004; 33: 979-87.
20. Thall PF, Champlin RE, Andersson BS. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 2004; 33: 1191-9.
21. Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B, et al. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 805-12.
22. Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, et al. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant 2004; 10: 614-23.
23. Jenke A, Freiberg-Richter J, Johne C, Knoth H, Schleyer E, Ehninger G, et al. Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005; 35: 627-8.
24. Kim SE, Lee JH, Choi SJ, Ryu SG, Lee KH. Morbidity and nonrelapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: A retrospective comparison of oral versus intravenous busulfan. Haematologica 2005; 90: 285-6.
25. Lee JH, Choi SJ, Kim SE, Park CJ, Chi HS, Lee MS, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005; 84: 321-30.
26. Oechtering D, Schiltmeyer B, Hempel G, Schwab M, Wurthwein G, Murdter T, et al. Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation. Anticancer Drugs 2005; 16: 337-44
27. Zwaveling J, Bredius RG, Cremers SC, Ball LM, Lankester AC, Teepe-Twiss IM, et al. Intravenous busulfan in children prior to stem cell transplantation: Study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005; 35: 17-23
28. Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006; 12: 770-7.
29. Fisher VL, Barnes YJ, Nuss SL. Pretransplant conditioning in adults and children: Dose assurance with intravenous busulfan. Oncol Nurs Forum 2006; 33: E36-43.
30. Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 472-9.
31. Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: A population pharmacokinetic study. Cancer Chemother Pharmacol 2006; 57: 191-8.
32. Oechtering D, Boos J, Hempel G. Monitoring of N,N-dimethyl-acetamide in children during i.v.-busulfan therapy by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 838: 129-34.
33. Takama H, Tanaka H, Nakashima D, Ueda R, Takaue Y. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 345-51.
34. Zwaveling J, den Hartigh J, Lankester AC, Guchelaar HJ, Egeler RM, Bredius RG. Once-daily intravenous busulfan in children prior to stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Anticancer Drugs 2006; 17: 1099-105.
35. Booth BP, Rahman A, Dagher R, Griebel D, Lennon S, Fuller D, et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol 2007; 47: 101-11.
36. Cho YH, Lim HA, Lee MH, Kim I, Lee JS, Park S, et al. Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation. Clin Transplant 2007; 21: 417-22.
37. Hoy SM, Lyseng-Williamson KA. Intravenous busulfan: In the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs 2007; 9: 271-8.
38. Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007; 13: 56-64
39. Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA, et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007; 13: 814-21.
40. Ryu SG, Lee JH, Choi SJ, Lee YS, Seol M, Hur EH, et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1095-105.
41. Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 307-14.
42. Vassal G, Michel G, Esperou H, Gentet JC, Valteau-Couanet D, Doz F, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008; 61: 113-23.
43. Cheuk DK, Wang P, Lee TL, Chiang AK, Ha SY, Lau YL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 935-44.
44. Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14: 220-8.
45. Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: A matched pair analysis. Biol Blood Marrow Transplant 2007; 13: 299-306.
46. Shaughnessy P, Alexander W, Tran H, Ririe D, Splichal J, Pollack M, et al. Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma. Mil Med 2006; 171: 161-5.
47. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 2006; 20: 322-8.
48. Mamlouk K, Saracino G, Berryman RB, Fay JW, Pineiro LA, Vance EA, et al. Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: Reduced toxicity without the need for pharmacokinetic monitoring. Bone Marrow Transplant 2005; 35: 747-54
49. Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 88-98.
50. Storb R, Thomas ED, Buckner CD, Clift RA, Johnson FL, Fefer A, et al. Allogeneic marrow grafting for treatment of aplastic anemia. Blood 1974; 43: 157-80.
51. Deeg HJ, O'Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006; 108: 1485-91.
52. Hobbs JR, Hugh-Jones K, Shaw PJ, Downie CJ, Williamson S. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children. Bone Marrow Transplant 1986; 1: 201-8.
53. Banna GL, Aversa S, Sileni VC, Favaretto A, Ghiotto C, Monfardini S. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol 2004; 51: 171-89.
54. Shaw PJ, Hugh-Jones K, Hobbs JR, Downie CJ, Barnes R. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children. Bone Marrow Transplant 1986; 1: 193-200.
55. Sanders JE, Pritchard S, Mahoney P, Amos D, Buckner CD, Witherspoon RP, et al. Growth and development following marrow transplantation for leukemia. Blood 1986; 68: 1129-35.
56. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-88.
57. Santos GW. Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia-a review. Leuk Lymphoma 1993; 11 Suppl 1: 201-4.
58. Tutschka PJ, Copelan EA, Kapoor N. Replacing total body irradiation with busulfan as conditioning of patients with leukemia for allogeneic marrow transplantation. Transplant Proc 1989; 21: 2952-4.
59. Copelan EA, Biggs JC, Avalos BR, Szer J, Cunningham I, Klein JP, et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J Clin Oncol 1992; 10: 237-42.
60. Copelan EA, Deeg HJ. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 1992; 80: 1648-58.
61. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-53.
62. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820-6.
63. Bleyzac N, Barou P, Aulagner G. Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma. J Chromatogr B Biomed Sci Appl 2000; 742: 427-32.
64. Chen TL, Grochow LB, Hurowitz LA, Brundrett RB. Determination of busulfan in human plasma by gas chromatography with electron-capture detection. J Chromatogr 1988; 425: 303-9.
65. dos Reis EO, Vianna-Jorge R, Suarez-Kurtz G, Lima EL, Azevedo DA. Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19: 1666-74.
66. Ehrsson H, Hassan M. Determination of busulfan in plasma by GCMS with selected-ion monitoring. J Pharm Sci 1983; 72: 1203-5.
67. Embree L, Burns RB, Heggie JR, Phillips GL, Reece DE, Spinelli JJ, et al. Gas-chromatographic analysis of busulfan for therapeutic drug monitoring. Cancer Chemother Pharmacol 1993; 32: 137-42.
68. Hara S, Tsuchie M, Tsujioka R, Kimura M, Fujii M, Kuroda T, et al. High-performance liquid chromatographic quantification of busulfan in human serum after fluorescence derivatization by 2- naphthalenethiol. Anal Sci 2000; 16: 287-91.
69. Heggie JR, Wu M, Burns RB, Ng CS, Fung HC, Knight G, et al. Validation of a high-performance liquid chromatographic assay method for pharmacokinetic evaluation of busulfan. J Chromatogr B Biomed Sci Appl 1997; 692(2): 437-44.
70. Kellogg MD, Law T, Sakamoto M, Rifai N. Tandem mass spectrometry method for the quantification of serum busulfan. Ther Drug Monit 2005; 27: 625-9.
71. Murdter TE, Coller J, Claviez A, Schonberger F, Hofmann U, Dreger P, et al. Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry. Clin Chem 2001; 47: 1437-42.
72. Peris JE, Latorre JA, Castel V, Verdeguer A, Esteve S, Torres- Molina F. Determination of busulfan in human plasma using high-performance liquid chromatography with pre-column derivatization and fluorescence detection. J Chromatogr B Biomed Sci Appl 1999; 730: 33-40.
73. Quernin MH, Poonkuzhali B, Medard Y, Dennison D, Srivastava A, Krishnamoorthy R, et al. Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol. J Chromatogr B Biomed Sci Appl 1998; 709: 47-56.
74. Quernin MH, Poonkuzhali B, Medard Y, Dennison D, Srivastava A, Krishnamoorthy R, et al. High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol. J Chromatogr B Biomed Sci Appl 1999; 721: 147-52.
75. Quernin MH, Duval M, Litalien C, Vilmer E, Aigrain EJ. Quantification of busulfan in plasma by liquid chromatography-ion spray mass spectrometry. Application to pharmacokinetic studies in children. J Chromatogr B Biomed Sci Appl 2001; 763(1-2): 61-9.
76. Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H, et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002; 29: 963-5.
77. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-6.
78. Sandstrom M, Karlsson MO, Ljungman P, Hassan Z, Jonsson EN, Nilsson C, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant 2001; 28: 657-64.
79. Regazzi MB, Locatelli F, Buggia I, Bonetti F, Zecca M, Pregnolato M, et al. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation. Clin Pharmacol Ther 1993; 54: 45-52.
80. Buggia I, Locatelli F, Regazzi MB, Zecca M. Busulfan. Ann Pharmacother 1994; 28: 1055-62.
81. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 1995; 23: 1110-6.
82. Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996; 37: 247-53.
83. Pawlowska AB, Blazar BR, Angelucci E, Baronciani D, Shu XO, Bostrom B. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 1997; 20: 915-20.
84. Baker KS, Bostrom B, DeFor T, Ramsay NK, Woods WG, Blazar BR. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. Bone Marrow Transplant 2000; 26: 607-14.
85. Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, et al. Individualizing high-dose oral busulfan: Prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26: 463-70.
86. Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1013-18.
87. Krivoy N, Hoffer E, Tabak A, Elhasid R, Arush MW, Stein J, et al. Therapeutic monitoring of busulfan in pediatric bone marrow transplantation. Pediatr Hematol Oncol 2002; 19: 31-7.
88. McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 167-73.
89. Bostrom B, Enockson K, Johnson A, Bruns A, Blazar B. Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. Pediatr Transplant 2003; 7 Suppl 3: 12-8.
90. Bertholle-Bonnet V, Bleyzac N, Galambrun C, Mialou V, Bertrand Y, Souillet G, et al. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: A non-parametric population pharmacokinetic study. Ther Drug Monit 2007; 29: 177-84.
91. Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989; 24: 386-90.
92. Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood 1990; 75: 1723-7.
93. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, et al. Dose-dependent neurotoxicity of highdose busulfan in children: A clinical and pharmacological study. Cancer Res 1990; 50: 6203-7.
94. Hassan M, Oberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28: 130-4.
95. Vassal G, Deroussent A, Challine D, Hartmann O, Koscielny S, Valteau-Couanet D, et al. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992; 79: 2475-9.
96. Yeager AM, Wagner JE, Jr., Graham ML, Jones RJ, Santos GW, Grochow LB. Optimization of busulfan dosage in children under-going bone marrow transplantation: A pharmacokinetic study of dose escalation. Blood 1992; 80: 2425-8.
97. Vassal G, Challine D, Koscielny S, Hartmann O, Deroussent A, Boland I, et al. Chronopharmacology of high-dose busulfan in children. Cancer Res 1993; 53: 1534-7.
98. Vassa G, Fischer A, Challine D, Boland I, Ledheist F, Lemerle S, et al. Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease. Blood 1993; 82: 1030-4.
99. assan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, et al. Busulfan bioavailability. Blood 1994; 84: 2144-50.
100. Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994; 84: 2357-62.
101. Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma 1996; 22: 395-407
102. Hassan M, Fasth A, Gerritsen B, Haraldsson A, Syruckova Z, van den Berg H, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996; 18: 843-50.
103. Chattergoon DS, Saunders EF, Klein J, Calderwood S, Doyle J, Freedman MH, et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. Bone Marrow Transplant 1997; 20: 347-54.
104. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997; 57: 5509-16.
105. Gibbs JP, Yang JS, Slattery JT. Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro. Drug Metab Dispos 1998; 26: 52-5.
106. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT. Upregulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos 1999; 27: 1466-9.
107. Hassan M. The role of busulfan in bone marrow transplantation. Med Oncol 1999; 16: 166-76.
108. Poonkuzhali B, Srivastava A, Quemin MH, Dennison D, Aigrain EJ, Kanagasabapathy AS, et al. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24: 5-11.
109. Bolinger AM, Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000; 25: 925-30
110. Dupuis LL, Najdova M, Saunders EF. Retrospective appraisal of busulfan dose adjustment in children. Bone Marrow Transplant 2000; 26: 1143-7
111. Valteau-Couanet D, Benhamou E, Vassal G, Stambouli F, Lapierre V, Couanet D, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000; 25: 937-42.
112. Balasubramanian P, Chandy M, Krishnamoorthy R, Srivastava A. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation. Bone Marrow Transplant 2001; 28: 821-5.
113. Jacobson P, Park JJ, DeFor TE, Thrall M, Abel S, Krivit W, et al. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation, Bone Marrow Transplant 2001; 27: 855-61.
114. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos 2001; 29: 264-7.
115. Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O, et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 2003; 32: 979-86.
116. Dupuis LL, Najdova M, Saunders EF. Retrospective appraisal of busulfan dose adjustment in children. Bone Marrow Transplant 2003; 31: 729.
117. Schiltmeyer B, Klingebiel T, Schwab M, Murdter TE, Ritter CA, Jenke A, et al. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol 2003; 52: 209-16.
118. Shaw PJ, Nath C, Berry A, Earl JW. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages. Bone Marrow Transplant 2004; 34: 197-205.
119. Brice K, Valerie B, Claire G, Valerie M, Yves B, Gilles A, et al. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics. Pharmacoepidemiol Drug Saf 2008; 17(2): 135-43.
120. Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic idividualization of busulfan dosage regimens. Bone Marrow Transplant 2001; 28: 743-51.
121. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525-30.
122. Chandy M, Balasubramanian P, Ramachandran SV, Mathews V, George B, Dennison D, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia - the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 20051; 36: 839-45.
123. Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999; 93: 4436-40.
124. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta 2006; 368: 93-8.
125. Ehrsson H, Hassan M. Binding of busulfan to plasma proteins and blood cells. J Pharm Pharmacol 1984; 36: 694-6.
126. Bouligand J, Deroussent A, Simonnard N, Opolon P, Morizet J, Connault E, et al. Induction of glutathione synthesis explains pharmacodynamics of high-dose busulfan in mice and highlights putative mechanisms of drug interaction. Drug Metab Dispos 2007; 35: 306-14.
127. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996; 24: 1015-9
128. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 1996; 56: 3678-81.
129. Chen CL, Liu Q, Pui CH, Rivera GK, Sandlund JT, Ribeiro R, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997; 89: 1701-7.
130. Kim I, Keam B, Lee KH, Kim JH, Oh SY, Ra EK, et al. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogencic hematopoietic stem cell transplantation. Clin Transplant 2007; 21: 207-13.
131. Elmaagacli AH, Koldehoff M, Steckel NK, Trenschel R, Ottinger H, Beelen DW. Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant 2007; 40: 659-64.
132. Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001; 27: 1121-4.
133. Buggia I, Zecca M, Alessandrino EP, Locatelli F, Rosti G, Bosi A, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996; 16: 2083-8.
134. Nilsson C, Aschan J, Hentschke P, Ringden O, Ljungman P, Hassan M. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 429-35.
135. Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 1990; 82: 323-5.
136. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
137. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, et al. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055-60.
138. Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12: 1047-55.
139. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-30.
140. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, et al. Pharmacokinetics of busulfan: Correlation with venoocclusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
141. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255-67.
142. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-83.
143. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-42.
144. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-22.
145. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599-604.
146. Meresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children. Bone Marrow Transplant 1992; 10: 135-41.
147. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 909-13.
148. Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102: 31-5.
149. Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915-24.
150. McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13: 853-62.
151. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology 1996; 24: 830-7.
152. Scott B, Deeg HJ, Storer B, Chauncey T, Petersdorf S, Slattery J, et al. Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. Leuk Lymphoma 2004; 45: 2409-17.
153. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-8.
154. Clopes A, Sureda A, Sierra J, Queralto JM, Broto A, Farre R, et al. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage. Eur J Haematol 2006; 77: 1-6.
155. Hassan M, Ehrsson H, Smedmyr B, Totterman T, Wallin I, Oberg G, et al. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant 1989; 4: 113-4.
156. Grochow LB. Parenteral busulfan: Is therapeutic monitoring still warranted? Biol Blood Marrow Transplant 2002; 8: 465-7.
157. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100: 1201-7.
158. Hoffer E, Akria L, Tabak A, Scherb I, Rowe JM, Krivoy N. A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation. Ther Drug Monit 2004; 26: 331-5.
159. Tabak A, Hoffer E, Rowe JM, Krivoy N. Monitoring of busulfan area under the curve: Estimation by a single measurement. Ther Drug Monit 2001; 23: 526-8.
160. Lindley C, Shea T, McCune J, Shord S, Decker J, Harvey D, et al. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: Assessment of a test dose and first dose strategy. Anticancer Drugs 2004; 15: 453-9.
161. Takamatsu Y, Sasaki N, Eto T, Nagafuji K, Abe Y, Choi I, et al. Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation. Int J Hematol 2007; 86: 261-8.
162. Clift RA, Buckner CD, Appelbaum FR, Sullivan KM, Storb R, Thomas ED. Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood 1998; 92: 1455-6.